Tags

Type your tag names separated by a space and hit enter

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.

Abstract

OBJECTIVE

Schizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. In this study, we attempted to evaluate the effect of SFN on cognitive impairment in medicated patients with schizophrenia.

METHODS

We recruited a total of 10 outpatients with schizophrenia, all of whom gave informed consent. Participants took 3 tablets of SFN, consisting of 30 mg of SFN-glucosinolate per day, for 8 weeks. Clinical symptoms using the Positive and Negative Syndrome Scale (PANSS) and cognitive function using the Japanese version of CogState battery were evaluated at the beginning of the study and at week 8.

RESULTS

A total of 7 patients completed the trial. The mean score in the Accuracy component of the One Card Learning Task increased significantly after the trial. However, we detected no other significant changes in participants.

CONCLUSIONS

This result suggests that SFN has the potential to improve cognitive function in patients with schizophrenia.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Child Psychiatry, Chiba University Hospital, Chiba, Japan. Division of Law and Psychiatry, Chiba University Center for Forensic Mental Health, Chiba, Japan.

    ,

    Division of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health, Chiba, Japan.

    ,

    Department of Child Psychiatry, Chiba University Hospital, Chiba, Japan.

    ,

    Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.

    ,

    Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.

    ,

    Department of Psychiatry, Chiba University Hospital, Chiba, Japan.

    ,

    Kisarazu Hospital, Japan.

    ,

    Department of Child Psychiatry, Chiba University Hospital, Chiba, Japan. Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan. Department of Psychiatry, Chiba University Hospital, Chiba, Japan. Chiba University Center for Forensic Mental Health, 8Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan.

    Source

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    25912539

    Citation

    Shiina, Akihiro, et al. "An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients With Schizophrenia." Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology, vol. 13, no. 1, 2015, pp. 62-7.
    Shiina A, Kanahara N, Sasaki T, et al. An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia. Clin Psychopharmacol Neurosci. 2015;13(1):62-7.
    Shiina, A., Kanahara, N., Sasaki, T., Oda, Y., Hashimoto, T., Hasegawa, T., ... Hashimoto, K. (2015). An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia. Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology, 13(1), pp. 62-7. doi:10.9758/cpn.2015.13.1.62.
    Shiina A, et al. An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients With Schizophrenia. Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):62-7. PubMed PMID: 25912539.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia. AU - Shiina,Akihiro, AU - Kanahara,Nobuhisa, AU - Sasaki,Tsuyoshi, AU - Oda,Yasunori, AU - Hashimoto,Tasuku, AU - Hasegawa,Tadashi, AU - Yoshida,Taisuke, AU - Iyo,Masaomi, AU - Hashimoto,Kenji, PY - 2014/06/23/received PY - 2014/09/30/revised PY - 2014/10/02/accepted PY - 2015/4/28/entrez PY - 2015/4/29/pubmed PY - 2015/4/29/medline KW - Clinical trial KW - CogState KW - Executive function KW - Schizophrenia KW - Sulforafan SP - 62 EP - 7 JF - Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology JO - Clin Psychopharmacol Neurosci VL - 13 IS - 1 N2 - OBJECTIVE: Schizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. In this study, we attempted to evaluate the effect of SFN on cognitive impairment in medicated patients with schizophrenia. METHODS: We recruited a total of 10 outpatients with schizophrenia, all of whom gave informed consent. Participants took 3 tablets of SFN, consisting of 30 mg of SFN-glucosinolate per day, for 8 weeks. Clinical symptoms using the Positive and Negative Syndrome Scale (PANSS) and cognitive function using the Japanese version of CogState battery were evaluated at the beginning of the study and at week 8. RESULTS: A total of 7 patients completed the trial. The mean score in the Accuracy component of the One Card Learning Task increased significantly after the trial. However, we detected no other significant changes in participants. CONCLUSIONS: This result suggests that SFN has the potential to improve cognitive function in patients with schizophrenia. SN - 1738-1088 UR - https://www.unboundmedicine.com/medline/citation/25912539/full_citation L2 - http://www.cpn.or.kr/journal/journal_view.html?year=2015&vol=13&num=1&page=62 DB - PRIME DP - Unbound Medicine ER -